Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MGLL | Q99685 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8857213 | 0.98 | MEN1 (0.65) | MEN1KMT2ATSHRMGLLTDP1 | |
| SCHEMBL8857330 | 0.98 | MEN1 (0.65) | MEN1KMT2ATSHRMGLLTDP1 | |
| SCHEMBL8857178 | 0.98 | MEN1 (0.65) | MEN1KMT2ATSHRMGLLTDP1 | |
| SCHEMBL8857231 | 0.98 | MEN1 (0.65) | MEN1KMT2ATSHRMGLLTDP1 | |
| SCHEMBL8857521 | 0.95 | MEN1 (0.73) | MEN1KMT2ATSHRMGLLTDP1 | |
| SCHEMBL28106430 | 0.91 | TSHR (0.67) | MEN1KMT2ATSHRMGLLTDP1 | |
| SCHEMBL2549889 | 0.88 | MEN1 (0.58) | MEN1KMT2ATSHRMGLLTDP1 | |
| SCHEMBL27926923 | 0.88 | MEN1 (0.58) | MEN1KMT2ATSHRMGLLTDP1 | |
| SCHEMBL7519513 | 0.88 | MEN1 (0.58) | MEN1KMT2ATSHRMGLLTDP1 | |
| SCHEMBL13423720 | 0.87 | MEN1 (0.55) | MEN1KMT2ATSHRMGLLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105949716-B | Epoxy resin composition, prepreg, and fiber-reinforced composite material | 三菱化学株式会社 | 2019-01-04 | — | — | CN | disclosed |
| CN-105254848-B | Epoxy resin composition, prepreg, fiber-reinforced composite material, and method for producing same | 三菱化学株式会社 | 2018-07-24 | — | — | CN | disclosed |
| CN-103105733-B | Photosensitive composition | 住友化学株式会社 | 2017-11-24 | — | — | CN | disclosed |
| CN-103958560-B | Epoxy resin composition, prepreg, fiber-reinforced composite material, and method for producing same | MITSUBISHI RAYON CO.,LTD. (JP) | 2016-11-30 | — | — | CN | disclosed |
| CN-103703048-B | Curable epoxy resin composition | ABB研究有限公司 | 2016-09-21 | — | — | CN | disclosed |
| CN-105949716-A | EPOXY RESIN COMPOSITION, PREPREG, AND FIBER-REINFORCED COMPOSITE MATERIAL | 三菱丽阳株式会社 | 2016-09-21 | — | — | CN | disclosed |
| CN-103975002-B | Prepreg, fiber-reinforced composite material, method for producing same, and epoxy resin composition | 三菱丽阳株式会社 | 2016-07-06 | — | — | CN | disclosed |
| CN-105254848-A | EPOXY RESIN COMPOSITION, PREPREG, FIBER-REINFORCED COMPOSITE MATERIAL, AND METHOD FOR PRODUCING SAME | MITSUBISHI RAYON CO | 2016-01-20 | — | — | CN | disclosed |
| CN-103975002-A | Prepreg, fiber-reinforced composite material, method for producing same, and epoxy resin composition | MITSUBISHI RAYON CO | 2014-08-06 | — | — | CN | disclosed |
| CN-103958560-A | Epoxy resin composition, prepreg, fiber-reinforced composite material, and method for producing same | MITSUBISHI RAYON CO | 2014-07-30 | — | — | CN | disclosed |
| US-6521667-B1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2003-02-18 | — | — | US | disclosed |
| US-6432656-B1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| US-20020099220-A1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2002-07-25 | — | — | US | disclosed |
| US-6022894-A | Method of using calcilytic compounds | NPS PHARMACEUTICALS, INC. (US) | 2000-02-08 | — | — | US | disclosed |
| CN-1221401-A | Calcilytic compounds | NPS PHARMA INC (US) | 1999-06-30 | — | — | CN | disclosed |
| EP-0901459-A1 | CALCILYTIC COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1999-03-17 | — | — | EP | disclosed |
| US-5688823-A | ANTILIPEMIC AGENTS, ANTIGLYCEMIC AGENTS, OBESITY, GLUCOSE TOLERANCE INSUFFICIENCY, INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1997-11-18 | — | — | US | disclosed |
| WO-1997037967-A1 | CALCILYTIC COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1997-10-16 | — | — | WO | disclosed |
| US-5578620-A | TREATMENT OF DIABETES AND HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1996-11-26 | — | — | US | disclosed |
| EP-0678511-A2 | Thiazolidine and oxazolidine derivatives, their preparation and their medical use | SANKYO COMPANY LIMITED (JP) | 1995-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099220-A1 | Calcilytic compounds | CALCR, CASR, CALCRL | MEN1 337/4885KMT2A 4810/4885TSHR 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.